De Novo device
Quell-FM
Neurometrix, Inc. · Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms (QSQ, Class II) · First FDA decision May 18, 2022, newest May 18, 2022Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
0
Naming "Quell-FM"
MAUDE reports
0
Brand "Quell-FM", since 2015
PubMed studies
0
Mentioning "Quell-FM"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Quell-FM
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP)National determinationOn the books160.27Updated Feb 10, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative PainNational determinationOn the books10.2Updated Dec 2, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES)National determinationOn the books160.13Updated Aug 16, 2023
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Quell-FM", any status and sponsor, newest update first.
No registered device study names "Quell-FM".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Quell-FM", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QSQ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Quell-FM"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.